穴位自血疗法治疗支气管扩张症稳定期的临床研究

Clinical Study of Acupoint Autohemotherapy for Stable Bronchiectasis

目的观察穴位自血疗法治疗支气管扩张症稳定期的临床疗效。方法将70例支气管扩张症稳定期患者随机分为治疗组和对照组,每组35例。治疗组采用穴位自血疗法治疗,对照组采用口服盐酸氨溴索片治疗。观察两组治疗前后各项免疫指标[免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)、C3补体、C4补体]的变化情况,比较两组治疗后24 h痰量、肺功能指标[1秒用力呼气容积(FEV_(1))及FEV_(1)/用力肺活量(FVC)的比值]、改良医学研究委员会(mMRC)呼吸困难评分和圣乔治呼吸问卷(SGRQ)评分。结果治疗组治疗后各项免疫指标及FEV_(1)/FVC与对照组比较,差异均具有统计学意义(P<0.01)。两组治疗后24 h痰量、mMRC呼吸困难评分、SGRQ评分及FEV_(1)比较,差异均无统计学意义(P>0.05)。结论穴位自血疗法能调节支气管扩张症稳定期患者的免疫状态,改善其肺功能。

Objective To observe the clinical efficacy of acupoint autohemotherapy in treating stable bronchiectasis.Method Seventy patients with stable bronchiectasis were randomized into a treatment group and a control group,with 35 cases in each group.The treatment group was intervened by acupoint autohemotherapy,and the control group was treated with oral Ambroxol hydrochloride.Before and after the treatment,immune indicators[immunoglobulin A(IgA),immunoglobulin G(IgG),immunoglobulin M(IgM),C3,and C4]were observed;the 24-h sputum volume,pulmonary function parameters[forced expiratory volume in one second(FEV_(1))and FEV_(1)/forced vital capacity(FVC)],modified medical research council(mMRC)score for dyspnea,and St.George’s respiratory questionnaire(SGRQ)score were compared.Result After the treatment,the immune indicators and FEV_(1)/FVC in the treatment group were significantly different from those in the control group(P<0.01).There were no significant differences in the 24-h sputum volume,mMRC dyspnea score,SGRQ score,or FEV_(1) between the two groups(P>0.05).Conclusion Acupoint autohemotherapy can regulate the immune state and enhance pulmonary function in patients with stable bronchiectasis.